Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 10/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5387236 | 0.88 | METAP2 (0.62) | METAP2SMN1; SMN2GAAALDH1A1NPSR1 | |
| SCHEMBL5376665 | 0.88 | METAP2 (0.47) | METAP2SMN1; SMN2ALDH1A1HPGDKMT2A | |
| SCHEMBL5371746 | 0.88 | KMT2A (0.42) | METAP2SMN1; SMN2ALDH1A1HPGDKMT2A | |
| SCHEMBL5392093 | 0.86 | METAP2 (0.49) | METAP2SMN1; SMN2GAAALDH1A1HPGD | |
| SCHEMBL5382055 | 0.85 | METAP2 (0.49) | METAP2HPGDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL5393592 | 0.85 | METAP2 (0.52) | METAP2SMN1; SMN2GAAALDH1A1NPSR1 | |
| SCHEMBL5376577 | 0.83 | METAP2 (0.47) | METAP2ALDH1A1NPSR1PIK3CAPIK3CB | |
| SCHEMBL5371990 | 0.82 | KDM4E (0.45) | METAP2ALDH1A1PIK3CAPIK3CBPIK3CG | |
| SCHEMBL5382952 | 0.82 | METAP2 (0.49) | METAP2SMN1; SMN2GAAALDH1A1NPSR1 | |
| SCHEMBL5373695 | 0.82 | METAP2 (0.54) | METAP2SMN1; SMN2GAAALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1223932-A4 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2003-01-15 | — | — | EP | claimed |
| EP-1223932-A1 | COMPOUNDS AND METHODS | SmithKline Beecham Corporation (US) | 2002-07-24 | — | — | EP | claimed |
| WO-2001024796-A1 | 1,2,4-TRIAZOLE DERIVATIVES, COMPOSITION, PROCESS OF MAKING AND METHODS OF USE | SMITHKLINE BEECHAM CORPORATION (US) | 2001-04-12 | — | — | WO | claimed |
| US-7304082-B2 | 1,2,4-triazole derivatives, compositions, process of making and methods of use | SMITHKLINE BEECHAM CORPORATION (US) | 2007-12-04 | — | — | US | disclosed |
| US-20050267185-A1 | 1,2,4-triazole derivatives, compositions, process of making and methods of use | SMITHKLINE BEECHAM CORPORATION | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267185-A1 | 1,2,4-triazole derivatives, compositions, process of making and methods of use | METAP2, METAP1, DNPEP | METAP2 1/4885SMN1; SMN2 4773/4885GAA 2089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.